Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The report emphasizes the value of the ATTC platform and the continuous development of potential pipelines [5][7] - The company is advancing innovative treatments for cancer and immune diseases, showcasing its proprietary ATTC platform and the latest progress in late-stage pipeline candidates [7] Financial Performance and Forecast - The company’s projected revenues for 2025, 2026, and 2027 are $567 million, $676 million, and $816 million respectively, with growth rates of -10.0%, 19.2%, and 20.7% [6][8] - The expected net profit for 2025, 2026, and 2027 is $426 million, $94 million, and $138 million respectively, with growth rates of 1029.3%, -78.0%, and 46.7% [6][8] - The report anticipates a reasonable equity value of HKD 26.9 billion based on DCF calculations, assuming a perpetual growth rate of 2% and a WACC of 9.43% [7] Pipeline Development - The ATTC platform is a novel cancer precision therapy development platform that combines monoclonal antibodies with proprietary targeted small molecule inhibitors, aiming for superior anti-tumor activity and safety [7] - The first potential pipeline candidate from this platform is HMPL-A251, which has shown promising anti-tumor efficacy and tolerability in preclinical studies, with plans to enter clinical development by the end of 2025 [7] - Ongoing projects include: 1. FRUSICA-2 study for fruquintinib combined with sintilimab in renal cell carcinoma [7] 2. SANOVO study for savolitinib in non-small cell lung cancer [7] 3. Ongoing studies for surufatinib in pancreatic cancer [7] 4. HMPL-453 for intrahepatic cholangiocarcinoma, with plans for a new drug application in mid-2026 [7]

Core Viewpoint - The company is set to share its latest key research and business developments at an investor meeting on October 31, 2025, focusing on advancements in innovative cancer and immune disease treatments [1] Group 1: Research and Development Progress - The event will highlight the company's progress in its next-generation antibody-drug conjugate (ATTC) platform and the latest developments in its late-stage pipeline candidates [1] - The Chief Medical Officer emphasized the company's mission to address critical unmet medical needs in cancer and immune diseases, driving the commitment to advance innovative therapies [1] Group 2: Strategic Vision - The ATTC platform is expected to redefine precision treatment for cancer, supported by a robust product pipeline and collaborative strategies [1] - The company expresses confidence in its ability to provide transformative treatment options for patients globally in the fields of cancer and immune diseases [1]

Core Viewpoint - The company is focused on advancing innovative treatments for cancer and immune diseases, showcasing its latest developments in the ATTC platform and late-stage pipeline candidates [1] Group 1: R&D Progress - The company shared key advancements in its innovative cancer and immune disease treatments during an investor meeting [1] - The ATTC platform is expected to redefine precision treatment for cancer, addressing unmet medical needs in these fields [1] Group 2: Leadership Insights - Dr. Shi Ming, the company's R&D head and Chief Medical Officer, emphasized the mission to meet critical unmet medical needs in cancer and immune diseases [1] - The company is confident in its ability to provide transformative treatment options for patients globally, supported by a robust product pipeline and collaboration strategies [1]

Core Viewpoint - The study demonstrates that patient-derived cancer organoids (PDCO) can accurately predict the response of locally advanced rectal cancer (LARC) to chemoradiation, supporting the use of Irinotecan as a candidate for neoadjuvant therapy in LARC patients [2][4][7]. Group 1 - The research established a biobank of rectal cancer organoids (RCO) from LARC patient samples, confirming that PDCO can predict LARC responses to chemoradiation [4][7]. - The accuracy of predicting clinical outcomes using organoids was found to be 92.50% in the discovery cohort and 93.75% in the validation cohort, indicating a high predictive capability [4][7]. - The study highlighted the importance of the timing of organoid survival data collection, which significantly affects the correlation between organoid treatment responses and patient clinical outcomes [4][7]. Group 2 - The organoids exhibited both synergistic (3.91%) and antagonistic (4.69%) effects in response to combined treatment, showcasing the complexity of treatment interactions [4][7]. - Irinotecan, a topoisomerase I inhibitor, was identified as a candidate drug for neoadjuvant therapy in LARC patients, emphasizing its role in inducing apoptosis in tumor cells [4][7]. - The systematic analysis of rectal cancer organoid responses to chemoradiation may significantly influence the broader application of organoid technology in precision cancer treatment [8].